Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid TumorsGREGORC, Vanesa; DE BRAUD, Filippo G; GHIO, Domenico et al.Clinical cancer research (Print). 2011, Vol 17, Num 7, pp 1964-1972, issn 1078-0432, 9 p.Article

Rapid communication absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinibCURIGLIANO, Giuseppe; PELOSI, Giuseppe; DE PAS, Tommaso et al.The Prostate. 2007, Vol 67, Num 6, pp 603-604, issn 0270-4137, 2 p.Article

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lungCONFORTI, Fabio; CATANIA, Chiara; DE PAS, Tommaso Martino et al.Lung cancer. 2013, Vol 81, Num 3, pp 440-444, issn 0169-5002, 5 p.Article

Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trialsDE PAS, Tommaso; GIOVANNINI, Monica; VERONESI, Giulia et al.Critical reviews in oncology/hematology. 2012, Vol 83, Num 3, pp 432-443, issn 1040-8428, 12 p.Article

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaJOHANNSEN, Manfred; SPITALERI, Gianluca; MILLER, Kurt et al.European journal of cancer (1990). 2010, Vol 46, Num 16, pp 2926-2935, issn 0959-8049, 10 p.Article